TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30588277

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person (IP) treatment
Number of subjects: 0
Study: 27771799

Group type: EXPERIMENTAL
Intervention: Salbutamol (1000 µg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 24253140

Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch in 0.9% saline (Voluven)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Balanced solution of 6% hydroxyethyl starch (Plasma Volume Redibag)
Number of subjects: 12
Study: 21818062

Group type: EXPERIMENTAL
Intervention: Experimental initiation and standard 2.0 maintenance BPSPs (EXP-STD group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard BPSPs (not explicitly named)
Number of subjects: 105
Study: 20362992

Group type: EXPERIMENTAL
Intervention: Interpersonal-psychotherapy-oriented childbirth psychoeducation programme (2 x 90-min classes + telephone follow-up)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Routine childbirth education (control group)
Number of subjects: 194
Study: 18630544

Group type: EXPERIMENTAL
Intervention: Acupuncture and Moxibustion
Number of subjects: 686
Study: 15704613

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 20 mg rabeprazole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral administration of 20 mg rabeprazole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both treatments (oral and intravenous)
Number of subjects: 28
Study: 12915378

Group type: EXPERIMENTAL
Intervention: miniCEX rating scale (9-point scale)
Number of subjects: 40
Study: 10329814

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7795397

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1780994

Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate 2500 mg over 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis 500 mg weekly for 27 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis 500 mg weekly for 27 weeks after nodulectomy and acute malaria treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical and chemotherapeutic treatment
Number of subjects: 0
Study: 7026074

Group type: EXPERIMENTAL
Intervention: Adriamycin‐vincristine (AV)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: AV plus dibromodulcitol (AVD)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: AV plus ICRF-159 (AVI)
Number of subjects: 268
Study: 31926827

Group type: EXPERIMENTAL
Intervention: GnRH agonist luteal support 0.1 mg SC every other day, starting on day 3 post egg retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: 80 Âµg recombinant hCG (Ovitrelle, Merck Serono SA) as control, single dose on day 3 post-egg retrieval
Number of subjects: 0
Study: 31604069

Group type: EXPERIMENTAL
Intervention: High power condition
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Low power condition
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: General positive emotion condition
Number of subjects: 55
Study: 28120559

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)‐guided PCI
Number of subjects: 666
Study: 25899956

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg orally twice a day for 4 days (10 doses total)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 114
Study: 24306214

Group type: EXPERIMENTAL
Intervention: Normal protein diet (NPD) - 1.2 g protein ⋅ kg body weight(‐1) ⋅ d(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low protein diet (LPD) - 0.1 g protein ⋅ kg body weight(‐1) ⋅ d(‐1)
Number of subjects: 20
Study: 23172127

Group type: EXPERIMENTAL
Intervention: Multimodal quality improvement intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 22
Study: 19763530

Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (RPMS) applied over the first sacral radix, 10 series of 10 seconds duration, frequency of 20 Hz, 1.2-fold intensity above motoric threshold
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 53
Study: 17823424

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Folic acid (400-800 microg/d)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Folic acid (5000 microg/d)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Folic acid (10,000 microg/d)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study: 15172273

Group type: EXPERIMENTAL
Intervention: En bloc isolation of pulmonary veins
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maze procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mitral valve correction alone
Number of subjects: 30
Study: 11524347

Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium 20 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium 40 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium 80 mg IV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9930595

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily p.o.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 10
Study: 8039123

Group type: EXPERIMENTAL
Intervention: Ocular ice pack therapy
Number of subjects: 62
Study: 3051876

Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MLCu250
Number of subjects: 600
Study: 4879883

Group type: EXPERIMENTAL
Intervention: tetracycline plus nystatin (Mysteclin)
Number of subjects: 111

Group type: COMPARATOR
Intervention: tetracycline
Number of subjects: 111
Study: 29016538

Group type: EXPERIMENTAL
Intervention: Healing time of 15.8 days
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Epithelialization time
Number of subjects: 219
Study: 28291957

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40IU)
Number of subjects: 19
Study: 26184311

Group type: EXPERIMENTAL
Intervention: Solid feed intake
Number of subjects: 528

Group type: COMPARATOR
Intervention: Milk replacer (control)
Number of subjects: 528
Study: 23345639

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 to 600 mg/d
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 21889769

Group type: EXPERIMENTAL
Intervention: Combination therapy with statins and fenofibric acid (FA)
Number of subjects: 2228
Study: 18066566

Group type: EXPERIMENTAL
Intervention: RAL (60 mg daily and continuously)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerat + 2 mg dienogest, continuously)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 15903364

Group type: EXPERIMENTAL
Intervention: Coreshorts compression shorts
Number of subjects: 13

Group type: COMPARATOR
Intervention: No compression shorts (control)
Number of subjects: 13
Study: 12780945

Group type: EXPERIMENTAL
Intervention: Spirospec
Number of subjects: 45

Group type: COMPARATOR
Intervention: Masterlab 4.0
Number of subjects: 45
Study: 10645754

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 11008

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 11008

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11008

Group type: EXPERIMENTAL
Intervention: Celecoxib (subset with sulfonamide hypersensitivity)
Number of subjects: 11008

Group type: COMPARATOR
Intervention: NSAIDs (subset with sulfonamide hypersensitivity)
Number of subjects: 11008

Group type: COMPARATOR
Intervention: Placebo (subset with sulfonamide hypersensitivity)
Number of subjects: 11008
Study: 8882114

Group type: EXPERIMENTAL
Intervention: Respirators without a particle filter
Number of subjects: 19

Group type: COMPARATOR
Intervention: Respirators with a particle filter
Number of subjects: 19
Study: 1993961

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal) 5 ml/kg
Number of subjects: 446

Group type: COMPARATOR
Intervention: Air (control group) 5 ml/kg
Number of subjects: 446
Study: 6501237

Group type: EXPERIMENTAL
Intervention: 30 mg yohimbine hydrochloride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg yohimbine hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31132570

Group type: EXPERIMENTAL
Intervention: Intrinsic state motivation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: State success motivation
Number of subjects: 105
Study: 29720119

Group type: EXPERIMENTAL
Intervention: Baby boomers and post baby boomers
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Caregiving without choice and longer hours on caregiving tasks
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Post baby boomer caregivers
Number of subjects: 1069
Study: 27055606

Group type: EXPERIMENTAL
Intervention: Jet injection of lidocaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Needle infiltration of lidocaine
Number of subjects: 44
Study: 24645800

Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA test
Number of subjects: 9989

Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 9989

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 9989
Study: 22503057

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) plus bare-metal stent (BMS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 150
Study: 20159134

Group type: EXPERIMENTAL
Intervention: Painful shoulders (n=10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Asymptomatic shoulders (n=16)
Number of subjects: 26
Study: 17587750

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study: 14532938

Group type: COMPARATOR
Intervention: Thrombolysis in a community hospital (group A, n=99)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Thrombolysis during immediate transportation for coronary angioplasty (group B, n=100)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Immediate transportation for coronary angioplasty without thrombolysis (group C, n=101)
Number of subjects: 300
Study: 11115952

Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention (experimental group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual medical follow-up (control group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Adherence >/=95%
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Poor effort to take medication
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: High self-perceived capacity to follow the regimen
Number of subjects: 116
Study: 8941069

Group type: EXPERIMENTAL
Intervention: Sperm deformity index assessment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Sperm deformity index
Number of subjects: 158

Group type: COMPARATOR
Intervention: Proportion of normal sperm morphology
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Area under the ROC curve for sperm deformity index
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pregnancy outcome
Number of subjects: 158
Study: 14628738

Group type: EXPERIMENTAL
Intervention: HTK solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: EuroCollins solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 0
Study: 4030486

Group type: EXPERIMENTAL
Intervention: UV-filtering posterior chamber intraocular lens (IOL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary capsulotomy during extracapsular cataract surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyaluronidase added to retrobulbar anesthetic injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical indomethacin before surgery and for nine months postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 29083477

Group type: EXPERIMENTAL
Intervention: Intranasal birch pollen allergen Bet v 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal omalizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26906034

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg twice daily for 3 days followed by once daily for 11 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24694077

Group type: EXPERIMENTAL
Intervention: recombinant human platelet-derived growth factor-BB + β-tricalcium phosphate + coronally advanced flap (CAF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: connective tissue graft (CTG) + coronally advanced flap (CAF)
Number of subjects: 20
Study: 22576981

Group type: EXPERIMENTAL
Intervention: Support intervention (1 week residential, followed by 4 days of follow-up 2 months later)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Routine control group
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Support intervention
Number of subjects: 382
Study: 20556260

Group type: EXPERIMENTAL
Intervention: Mucosa-supported implant-retained overdenture (OD) with an ovoid bar (two implants; design 1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mucosa-supported implant-retained overdenture (OD) with multiple ovoid bars (four implants; design 2)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Rigid implant-supported prosthesis (ISP) with a milled bar (design 3)
Number of subjects: 76

Group type: COMPARATOR
Intervention: All designs (OD design 1, OD design 2, ISP)
Number of subjects: 76
Study: 18391103

Group type: EXPERIMENTAL
Intervention: eGFR <40 mL/min
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: eGFR 40 to 60 mL/min
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: eGFR >60 mL/min
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Adjustment for incident congestive heart failure and myocardial infarction
Number of subjects: 2763
Study: 15826311

Group type: EXPERIMENTAL
Intervention: Estrogen‐progestogen therapy
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo or no drugs
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Comparison of interested vs non-interested women
Number of subjects: 2000
Study: 12516831

Group type: EXPERIMENTAL
Intervention: Combination of EMD and GTR using a collagen membrane
Number of subjects: 61

Group type: COMPARATOR
Intervention: GTR monotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: EMD monotherapy
Number of subjects: 61
Study: 11938780

Group type: EXPERIMENTAL
Intervention: bifidobiogen
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no bifidobiogen)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 153
Study: 8572785

Group type: EXPERIMENTAL
Intervention: Cryopreservation (Group V and Group VI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 60
Study: 1743444

Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole echocardiography test (DET: 2D-echo monitoring during dipyridamole infusion up to 0.84 mg/kg over 10 minutes)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Maximal symptom limited bicycle exercise electrocardiography test (EET)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole echocardiography test (DET)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Wall Motion Score Index at peak dipyridamole
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Number of stenotic coronary vessels
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography positivity
Number of subjects: 477
Study: 6124470

Group type: EXPERIMENTAL
Intervention: 1.5 mg bromazepam
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 3 mg bromazepam
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31305186

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 31050201

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg plus 45 mL NaP (P-NaP)
Number of subjects: 189

Group type: COMPARATOR
Intervention: 90 mL NaP in two split doses (90-NaP)
Number of subjects: 189
Study: 27886382

Group type: EXPERIMENTAL
Intervention: Cucumis sativus seed extract (500 mg daily for 6 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (one capsule daily for 6 weeks)
Number of subjects: 47
Study: 26186444

Group type: EXPERIMENTAL
Intervention: Morning exercise (cycling, 45 min, 50%VO2peak)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Evening exercise (cycling, 45 min, 50%VO2peak)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control session (sitting rest) in the morning
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control session (sitting rest) in the evening
Number of subjects: 16
Study: 23893144

Group type: EXPERIMENTAL
Intervention: Kinesio‐Tex tape
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 21511152

Group type: EXPERIMENTAL
Intervention: Acrysof Restor SN6AD3 apodized multifocal IOL
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Acri.LISA 366D diffractive multifocal IOL
Number of subjects: 152

Group type: COMPARATOR
Intervention: Rezoom refractive multifocal IOL
Number of subjects: 152

Group type: COMPARATOR
Intervention: Acri.Smart 48S monofocal IOL
Number of subjects: 152
Study: 19553407

Group type: EXPERIMENTAL
Intervention: NB‐UVB plus oral vitamin E (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NB‐UVB only (group B)
Number of subjects: 24
Study: 17684214

Group type: EXPERIMENTAL
Intervention: Glutamine (0.25 mg/kg body weight) administered orally twice daily for 5 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (isonitrogenous, isoenergetic mix of nonessential amino acids) administered orally twice daily for 5 months
Number of subjects: 93
Study: 15320983

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 39
Study: 11419381

Group type: EXPERIMENTAL
Intervention: Dispositional instruction
Number of subjects: 120

Group type: COMPARATOR
Intervention: No dispositional instruction (uninstructed juries)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dispositional instruction (instructed juries)
Number of subjects: 120
Study: 9118772

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg QAM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8185727

Group type: EXPERIMENTAL
Intervention: 10-week exercise program (N = 31)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list control group (N = 23)
Number of subjects: 54
Study: 3520622

Group type: EXPERIMENTAL
Intervention: Low dose insulin infusion clamp study (8mU/M2/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High dose insulin infusion clamp study (40mU/M2/min)
Number of subjects: 16
Study: 30045737

Group type: EXPERIMENTAL
Intervention: Multimodal intervention lasting 12 months, implementing evidence-based practice related to peripheral venous catheters, including updated protocols, e-learning technologies, feedback, user and family information, and face-to-face training sessions.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 20
Study: 27343781

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine diluted with dextrose
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% ropivacaine diluted with saline
Number of subjects: 50
Study: 24799608

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with extravirgin olive oil
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 235
Study: 22650119

Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding combined with western medicine routine therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine therapy group (western medicine routine therapy)
Number of subjects: 60
Study: 20980427

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.3 or 0.5 mg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 151
Study: 18614167

Group type: EXPERIMENTAL
Intervention: 20 IU/kg LPS
Number of subjects: 18
Study: 15804905

Group type: EXPERIMENTAL
Intervention: Coverage of HIV/AIDS risk factors in Aboriginal newspapers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Identification of high-risk groups in media coverage
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: General portrayal of HIV/AIDS risk in Aboriginal media
Number of subjects: 31
Study: 11897462

Group type: EXPERIMENTAL
Intervention: Telephone-delivered motivational counseling (3 sessions)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 316
Study: 12027564

Group type: EXPERIMENTAL
Intervention: CD4zeta gene-modified T cells
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unmodified T cells
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 9695060

Group type: EXPERIMENTAL
Intervention: Workers with urine mercury concentration between 51 and 150 micrograms l-1
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Workers with urine mercury concentrations above 150 micrograms l-1
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Urine mercury concentrations
Number of subjects: 113
Study: 8083550

Group type: EXPERIMENTAL
Intervention: Puvasol in combination with topical tar therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Puvasol alone
Number of subjects: 50